About

I am an award-winning writer, editor, photographer and designer with more than 30 years of experience in the media. After studying at the University of Leeds, then London and Anglia HEC, I moved to Canada in the 1980s and started out on the radio while also writing for various music and sports publications, and doing freelance photography. I then edited some magazines before working at a science organization, doing communications and editing publications in a programming language called LaTeX that was challenging but exciting.

Following that, I edited a newspaper, spent some time in the US, and then moved back to the UK where I edited a food B2B publication.
I’ve written, and taken photographs for, hundreds of publications around the world, as well as for books, album covers, DVDs, and shot coverage for documentaries. I’ve edited books, written nine of my own, and done redesigns for several publications. And now I’m writing about biotech, as well as creating videos and a weekly podcast.

I’ve done other things, like running an aquarium, teaching photography and drumming (not at the same time), and running football (soccer) refereeing courses.

In what spare time I have, I love spending time with my wife, son and dog, challenging hikes up the Scottish hills (and down again), playing and writing music, watching baseball and soccer, and collecting memorabilia and autographs.

Articles by Jim Cornall

MinervaX raises €72M to develop Group B Streptococcus vaccine

European Commission approves Dupixent as first and only targeted prurigo nodularis medicine

Cell reprogramming can reverse fibrosis after heart attack

Charcot-Marie-Tooth study to get $250K grant

EMA gives Myrtelle’s Canavan disease gene therapy candidate OD designation 

Solve Therapeutics launches to tackle cancer

ADVERTISEMENT

Cyclica and SK Chemicals to co-develop novel therapeutics

Replay targets genetic brain disorders with new gene therapy company, Kaleibe

STORM Therapeutics closes $30M Series B financing

NMD Pharma cleared for spinal muscular atrophy trial

ImaginAb launches trial to study neoadjuvant immunotherapy

Etcembly reveals breakthrough in optimizing TCR assets

ADVERTISEMENT